Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer.

Trial Profile

Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Figitumumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ADVIGO
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Feb 2012 Planned End Date changed from 1 Feb 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 20 Oct 2011 Planned end date changed from 1 Jul 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 26 Jul 2010 New source identified and integrated (M.D. Anderson Cancer Center record, 2009-0049).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top